February 2, 2026 (MLN): Highnoon Laboratories Limited (PSX: HINOON) is exploring a potential acquisition of a target company, aimed to strengthen its strategic position and enhance business growth.

The move is expected to support expansion of the company’s business footprint, broaden its product portfolio, and create operational and commercial synergies, including improved market access and distribution efficiencies.

The acquisition is currently under evaluation and will proceed following comprehensive due diligence, negotiation, and execution of definitive agreements, along with receipt of necessary corporate and regulatory approvals, the on PSX revealed today.

Highnoon Laboratories is committed to keeping stakeholders informed as the process advances.

This strategic move could significantly bolster Highnoon’s competitive position in the pharmaceutical sector, opening opportunities for portfolio diversification and revenue growth in both domestic and regional markets.